Condições
18 condições de saúde com pesquisa de suplementos baseada em evidências
Explore health conditions with evidence-graded supplement recommendations. Each condition page ranks ingredients by the strength of clinical research supporting them.
How We Grade Evidence
Cada página de condição classifica os ingredientes de suplementos pela força da evidência clínica. Veja o que cada nota significa:
Strong Evidence
Multiple randomized controlled trials (RCTs) or meta-analyses with consistent positive results and large sample sizes.
Good Evidence
At least one RCT with mostly consistent results across studies. Evidence suggests benefit but more research may be needed.
Some Evidence
Small studies or observational data with some positive signals. Promising but insufficient for strong recommendations.
Very Early Research
In vitro studies, case reports, or pilot studies only. Early-stage research that requires clinical validation.
Ulcerative Colitis (UC)
~0.3% in Western countries; peak onset 15-30 years
Gastroesophageal Reflux Disease (GERD)
20-30% in Western populations; 5-10% in Asia
Chronic Constipation
15-20% of adults globally; increases with age; more common in women
Acute Diarrhea
1.7 billion cases of childhood diarrhea globally per year; 525,000 deaths
Antibiotic-Associated Diarrhea (AAD)
5-39% of antibiotic users; varies by antibiotic class
Clostridioides difficile Infection (CDI)
500,000 infections/year in the US; 29,000 deaths
Functional Dyspepsia
10-20% of the general population
Increased Intestinal Permeability (Leaky Gut)
Prevalence uncertain; measurable by lactulose/mannitol ratio test. Common in IBD, celiac disease, alcoholism
Lactose Intolerance
65-70% of global population (varies widely by ethnicity: 5% Northern European to 90% East Asian)
Traveler's Diarrhea
30-70% of travelers to high-risk areas depending on destination
Peptic Ulcer Disease
5-10% lifetime prevalence; declining due to H. pylori treatment
Bloating and Intestinal Gas
15-30% of general population report regular bloating; more common in IBS patients (>75%)
Irritable Bowel Syndrome (IBS)
10-15% of global population; more common in women (2:1 ratio)
Crohn's Disease
~0.3% in Western countries; peak onset 15-35 years
Small Intestinal Bacterial Overgrowth (SIBO)
Estimated 6-15% in healthy population; up to 80% in IBS patients
Helicobacter pylori Infection
~50% of global population infected; higher in developing countries
Gut Dysbiosis
Prevalence not precisely defined; associated with Western diet, antibiotic use, and numerous chronic diseases
Inflammatory Bowel Disease (IBD) — General
~0.5% in Western countries; rising incidence in Asia and South America
Aviso Legal da FDA: Estas declarações não foram avaliadas pela Food and Drug Administration. Os produtos e informações neste site não se destinam a diagnosticar, tratar, curar ou prevenir qualquer doença. As notas de evidência apresentadas são baseadas em nossa análise de pesquisas revisadas por pares publicadas e não constituem aconselhamento médico. Sempre consulte seu profissional de saúde antes de iniciar qualquer regime de suplementação.